H
Helus Pharma
Helus Pharma is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms
About Helus Pharma
Cybin Inc. is a biopharmaceutical company focused on developing psychedelic-based therapies to address mental health disorders. The company operates in the pharmaceutical and healthcare markets, targeting conditions such as Major Depressive Disorder, Alcohol Use Disorder, Generalized Anxiety Disorder, and Neuroinflammation. Cybin's business model revolves around advancing its drug programs through rigorous preclinical and clinical studies, with the goal of obtaining FDA approval for its innovative treatments. The company generates revenue through the development and commercialization of its proprietary drug candidates, supported by a robust intellectual property portfolio with 50 granted or pending patent applications across six patent families. Cybin serves patients, healthcare providers, and the broader mental health community by offering groundbreaking therapeutic options. The company's scientific leadership boasts extensive experience in psychiatry, addiction, and psychedelics, having overseen 60 IND programs with the FDA and contributed to the development of multiple commercially available prescription drugs. Cybin is also committed to advancing psychedelic facilitation training to promote supportive healing in clinical settings.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2019
- Headquarters
- Toronto, Canada
- Listing
- IPO 2019
- Employees
- 102
- Open positions
- None listed
- Dealroom signal
- 91.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Psychedelic Drugs, Addiction, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 2 companies, latest Aug 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $50M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Nov 2025 | $175M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$148M | — |
| 2025 | $0 | — | −$121M | — |
| 2024 | $0 | — | −$58M | — |
| 2023 | $0 | — | −$40M | — |
| 2022 | $0 | -100% | −$47M | — |
| 2021 | $634K | — | −$22M | -3520.3% |
Growth signals
Latest recorded traffic for Helus Pharma is 32K monthly website visits, down 62.8% over the last three months. Helus Pharma's team grew 14.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Small PharmaLondon, United KingdomShort-duration psychedelic therapies for mental health conditions
$28Mvaluation
Adelia TherapeuticsBoston, United States
$16Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Innovating Capital
Series A6 investors entered at this stage
Noetic Fund
EQT Life Sciences
Janus Henderson Investors- KPKearny Venture Partners
RA Capital Management
Subversive Capital
Series B and later1 investor entered at this stage
Lincoln Park Capital Fund
Other known investors8 additional known investors
Acorn Bioventures
Altium Capital
Avidity Partners
Deep Track Capital
Logos Capital
Octagon Capital Advisors
Rosalind Capital Partners
Sphera Funds Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Helus Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Helus Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.